Navigation Links
IVI granted 2 US patents on dysentery vaccine inventions
Date:2/27/2012

SEOUL, KOREA The International Vaccine Institute (IVI), an international organization based in Seoul devoted to research on the development and introduction of vaccines for the developing world, reached a milestone in its aim to prevent and control dysentery (also commonly called shigellosis or bloody diarrhea), a deadly disease that affects several million people worldwide. This infectious disease, caused by the bacterial pathogen Shigella, is a major health problem in developing countries, as young children are particularly vulnerable to the disease. The United States Patent and Trademark Office recently issued two patents on "Novel Shigella protein antigens and methods" to IVI. These two patents will accelerate the Institute's current efforts in developing an effective and low-cost vaccine for use among impoverished communities afflicted by dysentery.

The Shigella vaccine patents, which will expire in 2029, are the most recently issued patents of IVI. IVI filed these two patents (Applications No. 12/603,574 and No. 12/692,187) following its discovery of novel common protein antigens in several Shigella species that could be used as the basis of a universal vaccine against bacillary dysentery. With the potential to provide cross-protection across species and serotypes of Shigella, this could be the first broadly protective vaccine against dysentery. The patents claim vaccine compositions comprising either of two novel conserved Shigella proteins and a conjugate molecule comprising an O-specific polysaccharide antigen of Shigella bacteria covalently bound to either of these Shigella proteins.

Dr. Cecil Czerkinsky, IVI's Deputy Director-General of Laboratory Sciences and Dr. Dong Wook Kim, Associate Professor at Hanyang University and former IVI scientist, reported the original discovery of the Shigella common protein antigens in a provisional patent application filed in October 2008. Dr. Czerkinsky commented, "We are extremely excited about the issuance of the Shigella vaccine patents. It further reinforces our belief that these common proteins, through their immunological properties, may be highly effective in preventing shigellosis, a diarrheal disease that claims countless lives of children every year, mainly in developing countries."

"This patent issuance is an important milestone on IVI's path of delivering a new vaccine against another killer infectious disease," added Dr. Christian Loucq, IVI's Director-General. "Furthermore, it underlies the dynamism and productivity of IVI scientists."


'/>"/>

Contact: Tae Kyung Byun
tkbyun@ivi.int
82-119-773-6071
International Vaccine Institute
Source:Eurekalert

Related biology news :

1. Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research
2. Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research
3. Company Granted Patent on Apparatus, Systems, and Methods for Gathering and Processing Wireless Biometric and Biomechanical Data
4. BIO-key(R) Granted Patent for Trusted Biometric Device Security Solution
5. 2009 Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research
6. BIO-key(R) Granted Patent to Secure Biometric Enrollments From Unauthorized Use
7. BIO-key(R) Granted Additional Patent for Biometric Security Solution
8. U.S. Supreme Court petitioned to review AMP, et al. lawsuit on gene patents
9. US Patent Office affirms Zamore Design Rule patents
10. Digital data forensic expert at NJIT to be feted by R&D council for data hiding patents
11. IEEE-USA pleased that Supreme Courts ruling preserves software patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... , February 21, 2017 Der ... US-Dollar wachsen. Nach einem Gespräch mit mehr als 50 Vertretern ... Hindernisse zu überwinden gilt, um diese Prognose zu realisieren. ... ... die Mobilisierung der finanziellen Mittel für die Biobank, die ...
(Date:2/13/2017)... FRANCISCO , Feb. 13, 2017  RSA ... centralized platform that is designed to enhance fraud ... latest release in the RSA Fraud & Risk ... enable organizations to leverage additional insights from internal ... tools to better protect their customers from targeted ...
(Date:2/9/2017)... 2017 The biomass boiler market report by ... boiler market globally in terms of revenue (US$ Mn) ... market for biomass boilers has been segmented on the ... country/region. The market based on feedstock type, has been ... & energy crops, urban residues, and others. On the ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... and NEW YORK , Feb. ... Lumeon , a leading digital health company, and ... provider of telemedicine and remote patient monitoring, announce ... telemedicine reimbursements.  DN Telehealth maximizes ... in real-time, extending consultations beyond a physical clinical ...
(Date:2/23/2017)... , Feb. 23, 2017 /PRNewswire/ - The Fight Against ... Cancer Research (OICR) are pleased to report that Fusion ... financing, with Johnson & Johnson Innovation – JJDC, Inc. ... venture groups HealthCap, TPG Biotechnology Partners, and Genesys Capital, ... ...
(Date:2/23/2017)... Feb. 23, 2017  Seattle,s upscale Capitol Hill neighborhood, with its ... place for a head lice treatment salon to set up ... Tuscan restaurant and a French bistro on E Madison Ave, ... aren,t just any old lice clinic, we pride ourselves on ... and release some of the stigma associated with lice. Everyone ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... a published evaluation of multiple immunoassay-based threat detection technologies by researchers from ... PathSensors’ CANARY® biosensor threat detection technology was found to have the best ...
Breaking Biology Technology: